Search

Displaying results 6741 - 6750 of 7674 in total
  1. Drug

    Ancremonam

    go.drugbank.com/drugs/DB19710
    Investigational

    Ancremonam has a monoisotopic molecular weight of 518.05 Da.

  2. Drug

    QRX-411

    go.drugbank.com/drugs/DB17868
    Experimental

    It addresses the underlying cause of Usher syndrome due to the c.7595-2144A>G mutation in the _USH2A_ gene.[L46777]

  3. Drug

    Cabamiquine

    go.drugbank.com/drugs/DB21477
    Investigational

    Cabamiquine has a monoisotopic molecular weight of 462.24 Da.

  4. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter.

  5. Drug

    AM336

    go.drugbank.com/drugs/DB06563
    Experimental

    Leconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.

  6. Drug

    HPV-16 trojan peptide vaccine

    go.drugbank.com/drugs/DB17496
    Investigational

    HPV-16 trojan peptide vaccine is an investigational cancer immunotherapy consisting of a novel Trojan peptide complex, composed of human papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific

  7. Drug

    Mubodina

    go.drugbank.com/drugs/DB17616
    Experimental

    Mubodina is an investigational drug developed by Adienne Pharma & Biotech. It is a recombinant human minibody directed against complement component C5.

  8. Drug

    CG7870

    go.drugbank.com/drugs/DB04981
    Investigational

    CG7870 is an oncolytic virus therapy for prostate cancer.

  9. Drug

    G305

    go.drugbank.com/drugs/DB17292
    Investigational

    G305 is an active component of CMB305 along with [LV305].[L47346]

  10. Drug

    Ralmitaront

    go.drugbank.com/drugs/DB19128
    Investigational

    Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or